首頁 > 市場調查報告書 > 製藥

骨疾病

市場調查報告書

商品編碼

1528970

骨質疏鬆症藥物市場 - 按類型、藥物類別、給藥途徑、配銷通路和預測，2024 年 - 2032 年

Osteoporosis Drugs Market - By Type, Drug Class, Route of Administration, Distribution Channel & Forecast, 2024 - 2032

出版日期: 2024年05月08日 | 出版商:

Global Market Insights Inc. | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於全球骨質疏鬆症盛行率不斷上升，2024年至2032年骨質疏鬆症藥物市場規模的複合年成長率將達到4.6%。根據美國國立衛生研究院的數據，到 2023 年，骨質疏鬆症將影響全球超過 2 億人。隨著老年人的成長，骨密度自然下降，使他們更容易發生骨折和骨骼相關疾病。久坐的生活方式、營養不良和吸煙等生活方式因素進一步加劇了骨質疏鬆症的風險。

包括雙磷酸鹽、荷爾蒙療法和生物製劑在內的新藥的開發也將為管理和預防骨質流失提供更有效的選擇。這些藥物不僅有助於減緩骨吸收，還可以促進骨形成，進而改善整體骨骼健康。加強對骨質疏鬆症的認知活動和診斷篩檢，以加強早期檢測和治療啟動也將推動產品需求。

整個產業分為類型、藥品類別、給藥途徑、配銷通路和地區。

根據類型，繼發性骨質疏鬆症領域的骨質疏鬆症藥物市場規模預計將成長到 2032 年，因為它與導致骨質流失的可識別原因和潛在條件有關。已知甲狀腺功能亢進、類風濕性關節炎和長期使用皮質類固醇等疾病會增加繼發性骨質疏鬆症的風險。這些潛在疾病的管理正在為骨質疏鬆症藥物的持續治療鋪平道路，以減輕骨質流失並降低骨折風險。

在分銷管道方面，零售藥房領域的骨質疏鬆藥物市場將在2024年至2032年間錄得顯著成長。同時提供廣泛的藥物選擇並確保可用性在當地社區。隨著全球骨質疏鬆症盛行率的增加，特別是在老齡化人口中，從零售藥局獲取藥物的便利性將鼓勵治療依從性和患者依從性。

預計到 2032 年，亞太地區骨質疏鬆藥物產業規模將以驚人的速度成長。隨著這一人群年齡的成長，與年齡相關的骨骼疾病的發生率將會激增，進一步需要有效的治療方案。旨在改善醫療基礎設施和促進預防性護理的政府措施也促進了區域市場的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 骨質疏鬆症盛行率增加
  - 骨折發生率不斷增加
  - 藥物開發的技術進步
- 產業陷阱與挑戰
  - 治療費用高
  - 嚴重病例療效有限
成長潛力分析
監管環境
管道分析
波特的分析
PESTEL分析
未來市場趨勢

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
原發性骨質疏鬆症
- 停經後骨質疏鬆症
- 老年骨質疏鬆症
- 特發性骨質疏鬆症
繼發性骨質疏鬆症

第 6 章：市場估計與預測：按藥物類別，2021 - 2032 年

主要趨勢
雙磷酸鹽
RANK配體抑制劑
副甲狀腺素類似物
荷爾蒙替代療法（HRT）
選擇性雌激素受體調節劑 (SERM)
其他藥物類別

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

主要趨勢
口服
可注射
其他給藥途徑

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥房
網路藥房

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Amgen Inc.
Apotex Inc.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eli Lilly and Company
GSK plc
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Radius Health, Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited
UCB S.A.

簡介目錄

Product Code: 9420

Osteoporosis drugs market size will depict a 4.6% CAGR from 2024 to 2032 driven by the increasing prevalence of osteoporosis globally. As per the National Institute of Health, osteoporosis affected over 200 million people globally in 2023. The aging population, particularly in developed countries, is contributing significantly to the rise in osteoporosis cases. With the growth of aging people, bone density naturally decreases, making them more susceptible to fractures and bone-related disorders. Lifestyle factors, such as sedentary lifestyles, poor nutrition, and smoking are further exacerbating the risk of osteoporosis.

The development of new drugs, including bisphosphonates, hormone therapies, and biologics, will also offer more effective options for managing and preventing bone loss. These medications not only help in slowing down bone resorption but also promote bone formation for improving overall bone health. Increasing awareness campaigns and diagnostic screenings for osteoporosis to enhance early detection and treatment initiation will also drive product demand.

The overall industry is divided into type, drug class, route of administration, distribution channel, and region.

Based on type, the osteoporosis drugs market size from the secondary osteoporosis segment is set to grow up to 2032 due to its association with identifiable causes and underlying conditions that contribute to bone loss. Conditions, such as hyperthyroidism, rheumatoid arthritis, and prolonged use of corticosteroids are known to increase the risk of secondary osteoporosis. The management of these underlying conditions is making way for consistent treatment with osteoporosis medications to mitigate bone loss and reduce the risk of fractures.

In terms of distribution channels, the osteoporosis drugs market from the retail pharmacy segment will record a notable growth rate between 2024 and 2032. Retail pharmacies play a crucial role in distributing osteoporosis medications directly to consumers while offering a wide range of drug options and ensuring availability in local communities. With the globally increasing osteoporosis prevalence, particularly among the aging population, the convenience of obtaining medications from retail pharmacies will encourage treatment adherence and patient compliance.

Asia Pacific osteoporosis drugs industry size is anticipated to grow at an impressive pace through 2032. Increasing life expectancy and aging populations across countries like Japan, China, and South Korea are contributing significantly to the rising prevalence of osteoporosis. As this population grows older, the incidence of age-related bone disorders will surge, further necessitating effective treatment options. Government initiatives aimed at improving healthcare infrastructure and promoting preventive care are also bolstering the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of osteoporosis
  - 3.2.1.2 Growing incidence of fractures
  - 3.2.1.3 Technological advancements in drug development
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Limited efficacy in severe cases
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Primary osteoporosis
- 5.2.1 Postmenopausal osteoporosis
- 5.2.2 Senile osteoporosis
- 5.2.3 Idiopathic osteoporosis
5.3 Secondary osteoporosis

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Bisphosphonates
6.3 RANK ligand inhibitors
6.4 Parathyroid hormone analogs
6.5 Hormone replacement therapy (HRT)
6.6 Selective estrogen receptor modulators (SERMs)
6.7 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectable
7.4 Other route of administrations

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa